Gaucher type 1 is a GBA1-driven multisystem disease concentrated in the Ashkenazi Jewish founder population — and the N370S genotype that predicts non-neuronopathic disease also carries a 20-fold Parkinson's risk.
Gaucher disease is an autosomal recessive lysosomal storage disorder caused by biallelic mutations in GBA1, producing deficient acid β-glucosidase (glucocerebrosidase) and accumulation of glucosylceramide in macrophages — the Gaucher cells that infiltrate spleen, liver, and bone marrow. Disease divides into three types by neurological involvement: type 1 (non-neuronopathic) accounts for more than 90% of patients; type 2 (acute neuronopathic, infantile, usually fatal in early childhood) and type 3 (chronic neuronopathic) are far rarer. Type 1 presents with splenomegaly, hepatomegaly, anemia, thrombocytopenia, and skeletal disease, not the primary CNS degeneration that defines types 2 and 3.
Genotype predicts phenotype. The N370S (c.1226A>G) variant, when present on at least one allele, is protective against neuronopathic disease and defines type 1; the L444P variant in the homozygous state is associated with neuronopathic types 2 and 3. Gaucher type 1 is markedly enriched in the Ashkenazi Jewish population, where carrier frequency is about 1 in 12–15 and disease frequency roughly 1 in 500–1,000, versus 0.70–1.75 per 100,000 in the general population. Penetrance is variable: prenatal carrier-screening cohorts show that most 'asymptomatic' N370S homozygotes in fact have measurable anemia, thrombocytopenia, splenomegaly, or bone marrow infiltration (Arch Intern Med 2010). Critically, GBA1 is the single most common genetic risk factor for Parkinson's disease, and diagnosed type 1 patients carry a lifetime PD risk ratio of 21.4 versus the general population (J Inherit Metab Dis 2010).
Gaucher disease types and GBA1 genotype–phenotype correlation
| Gaucher Type | Neurological Involvement | Share of Cases | Typical GBA1 Genotype | Key Features |
|---|---|---|---|---|
| Type 1 — non-neuronopathic | None (visceral & skeletal only) | >90% of cases | ≥1 N370S (c.1226A>G) allele | Splenomegaly, hepatomegaly, anemia, thrombocytopenia, bone disease; enriched in Ashkenazi Jews (~1 in 500–1,000) |
| Type 2 — acute neuronopathic | Severe, infantile-onset CNS | Rarest (<5%) | L444P homozygous / null / recombinant | Rapid neurodegeneration; typically fatal by age 2–4 |
| Type 3 — chronic neuronopathic | Progressive CNS, later onset | ~5% of cases | L444P homozygous | Oculomotor apraxia, seizures, plus visceral disease |
| Founder variant — N370S | Protective against neuronopathic disease | — | c.1226A>G heterozygous / homozygous | Ashkenazi carrier ~1 in 12–15; predicts type 1; variable penetrance |
Sources: Nalysnyk L et al. Hematology 2016 (PMID 27762169); Balwani M et al. Arch Intern Med 2010 (PMID 20837833); Bultron G et al. J Inherit Metab Dis 2010 (PMID 20177787).
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- General-population vs Ashkenazi Jewish prevalence and carrier frequency
- founder-variant concentration
- diagnosed and treated pool sizing for type 1
Delivers
- Genotype–phenotype correlation
- N370S protection against CNS disease
- L444P homozygosity and neuronopathic types
- penetrance and severity variability
Delivers
- Diagnostic delay drivers and misdiagnosis patterns
- the 21.4-fold Parkinson's risk
- carrier-screening and case-finding opportunities
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- Biallelic GBA1 mutations cause deficient acid β-glucosidase, driving glucosylceramide accumulation in Gaucher cells that infiltrate spleen, liver and bone marrow
- N370S predicts protection against neuronopathic disease while L444P in the homozygous state is linked to types 2 and 3
- Ashkenazi Jewish carrier frequency runs about 1 in 12–15, with disease frequency roughly 1 in 500–1,000, versus 0.70–1.75 per 100,000 in the general population
- Prenatal carrier-screening cohorts show most 'asymptomatic' N370S homozygotes actually have measurable anemia, thrombocytopenia or splenomegaly
- Type 1 accounts for more than 90% of cases and lacks the CNS degeneration that defines type 2 and type 3
- Type 2 is rarest, under 5% of cases and typically fatal by age 2–4, while type 3 (about 5%) presents oculomotor apraxia and seizures alongside visceral disease
- Type 1 presents with splenomegaly, hepatomegaly, anemia, thrombocytopenia and skeletal disease rather than primary CNS involvement
- Bone disease and cytopenias compound the visceral burden, driving much of the treatment-monitoring and quality-of-life impact
- Variable penetrance means many 'asymptomatic' N370S homozygotes in fact have measurable anemia, thrombocytopenia or splenomegaly on closer testing
- Diagnostic delay and misdiagnosis patterns underlie the gap between genetic risk and confirmed, treated diagnosis
- GBA1 is the single most common genetic risk factor for Parkinson's disease, independent of Gaucher diagnosis
- Diagnosed Gaucher type 1 patients carry a lifetime Parkinson's disease risk ratio of 21.4 versus the general population
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Gaucher Disease Landscape sources: Nalysnyk et al. Hematology 2016 (PMID 27762169) for epidemiology; Balwani et al. Arch Intern Med 2010 (PMID 20837833) for Ashkenazi Jewish carrier and homozygote frequency; Bultron et al. J Inherit Metab Dis 2010 (PMID 20177787) for the GBA1–Parkinson's link; and peer-reviewed GBA1 genotype–phenotype literature.
- Type 1 share (>90%) and general-population prevalence verified against Nalysnyk et al. Hematology 2016 (PMID 27762169)
- Ashkenazi Jewish carrier and homozygote frequency verified against Balwani et al. Arch Intern Med 2010 (PMID 20837833)
- 21.4-fold Parkinson's disease risk verified against Bultron et al. J Inherit Metab Dis 2010 (PMID 20177787)
- N370S / L444P genotype–phenotype correlation verified against peer-reviewed Gaucher genetics literature
Frequently asked questions
Commission this assessment
AXLRx Gaucher Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous characterisation of the US Gaucher type 1 population. Custom assessment in 72 hours.
Specify indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.